Lacosamide Treatment Protocol

Administration and Efficacy

The American Academy of Emergency Medicine recommends that both oral and intravenous formulations of lacosamide are bioequivalent and can be used interchangeably without dose adjustment or retitration, with a tolerability profile consistent with oral administration 1
The Mayo Clinic suggests monitoring for PR interval prolongation, as lacosamide causes small dose-related increases in cardiac conduction time, and exercising caution in patients with pre-existing cardiac conduction abnormalities 2
The Mayo Clinic also notes that lacosamide causes small dose-related increases in cardiac conduction time, and recommends monitoring for PR interval prolongation 3

The European Society for Medical Oncology recommends lacosamide over enzyme-inducing agents, such as phenytoin, carbamazepine, and phenobarbital, which interact with steroids and cytotoxic agents, due to its minimal drug-drug interactions 4
The European Society for Medical Oncology suggests continuing lacosamide as secondary prophylaxis until local tumor control is achieved in brain tumor patients with seizures, and prefers lacosamide and levetiracetam as first-line options due to efficacy and tolerability 4
The European Society for Medical Oncology also recommends avoiding primary seizure prophylaxis with lacosamide in seizure-free patients, such as brain tumor patients without seizure history 4

The American College of Emergency Physicians guidelines state that loading doses for lacosamide have not been studied and are not recommended for routine use, and both oral and IV formulations are available and safe 5, 6, 7
For adults with partial-onset seizures, initiate lacosamide at 50 mg twice daily (100 mg/day) and titrate to the recommended maintenance dose of 100-200 mg twice daily (200-400 mg/day) based on response and tolerability, with no loading dose recommended for non-emergent situations 5

Abrupt discontinuation of lacosamide must be avoided as withdrawal seizures can occur with sudden cessation 5, 6, 7
Small dose-related increases in PR interval have been observed, warranting caution in patients with cardiac conduction abnormalities 8

The European Medical Oncology society is not mentioned in the provided citations, however, physicians may consider levetiracetam or lacosamide over older AEDs to reduce side effects 9
Lacosamide does not cause the cognitive impairment, neuropsychiatric disorders, myelosuppression, or significant liver dysfunction commonly seen with traditional agents, making it a preferable option 9, 10
Lacosamide offers advantages over older antiepileptic drugs due to minimal drug-drug interactions and reduced side effect burden, as recommended by medical guidelines 9, 10

Lacosamide is approved exclusively for focal-onset seizures in adults, adolescents, and children ≥4 years as both monotherapy and adjunctive therapy, acting on voltage-gated sodium channels 11
The American Academy of Neurology recommends lacosamide for focal-onset seizures, specifically for patients requiring anticonvulsants without enzyme-inducing properties, such as those with brain tumors 12

The National Institute of Neurological Disorders and Stroke notes that lacosamide causes dose-related PR interval prolongation, requiring cardiac monitoring in patients with conduction abnormalities 11
The American Heart Association recommends considering lacosamide for patients on multiple medications due to its minimal drug-drug interactions compared to enzyme-inducing agents 12